UCB receives CHMP positive opinion of zilucoplan for the treatment of adults with generalised myasthenia gravis in Europe 15 September 2023 – UCB, a global biopharmaceutical company, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending granting marketing authorisation for…
Phase 3 Study Results Compare IPX203 to Immediate-Release Carbidopa/Levodopa for PD
IPX203 demonstrated statistically significant improvement in daily “Good On” time compared to optimised IR CD/LD, with fewer daily doses August 24th, 2023: Amneal Pharmaceuticals, Inc announced that JAMA Neurology has published results from the RISE-PD clinical study assessing the efficacy and safety of IPX203 versus optimised immediate-release carbidopa/levodopa (IR CD/LD) for the treatment of Parkinson’s disease (PD)….
Brain stimulation project could treat wide range of neurological disorders
21st August, 2023 Researchers from the University of Glasgow, UK are part of a cross-Europe project which is aiming to develop a revolutionary new method of treating a wide range of neurological disorders. The Wireless Deep Brain Stimulation Through Engineered Multifunctional Nanomaterials project, or BRAINSTORM, is setting out to develop tiny injectable magnets which could…
Can the scent of essential oils improve memory?
From Medscape, August 8th 2023. Inhaling a pleasant aroma during sleep has been linked to an improvement in memory, small-scale early research suggests. Researchers randomly assigned 43 older adults, aged 60 – 85 years, to receive either nightly exposure to essential oil scents delivered via a diffuser (n = 20; mean [SD] age, 70.1 [6.6]…
Ketogenic diet in RRMS
Study suggests benefits may be long lasting Following a ketogenic diet for six months significantly reduced measures of body fat and fatigue, eased disease symptoms, and improved exercise capacity, cognition, and arm and hand dexterity in people with relapsing-remitting multiple sclerosis (RRMS), a study has shown. The research, Ketogenic diet in relapsing multiple sclerosis: Patient perceptions, post-trial…
Oxygen for brain injuries – can it help patients?
Inhaling oxygen while learning a motor task helped healthy people learn more quickly and effectively, raising hopes for neurorehabilitation Scientists studying the impact of oxygen supplementation on motor learning have found a promising treatment that could help patients who have experienced neurological trauma recover old skills. “A simple and easy to administer treatment with 100%…
Epilepsy associated with CDKL5 Deficiency Disorder
European Commission Approval of ZTALMY® (ganaxolone) for the Adjunctive Treatment of Epileptic Seizures Associated with CDKL5 Deficiency Disorder 31 July 2023: Marinus Pharmaceuticals announced that the European Commission (EC) has granted approval of ZTALMY® (ganaxolone) oral suspension for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients two to…
AI enhances clinical decision-making in radiology
AI solution will help improve patient outcomes by providing timely and accurate detection of critical abnormalities Milton Keynes University Hospital NHS Foundation Trust (MKUH) will use Qure’s qER for automating the detection of critical and life-threatening abnormalities in head CT scans, including intracranial haemorrhages (ICH) caused by trauma, accidents or strokes. It is an FDA…
Positive CHMP opinion for multiple sclerosis biosimilar natalizumab
July 24, 2023 — Sandoz, a global leader in off-patent (generic and biosimilar) medicines, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), has adopted a positive opinion for marketing authorisation for first-of-a-kind biosimilar natalizumab developed by Polpharma Biologics. The authorisation covers treatment as a single disease-modifying…
